Journal of Clinical Infectious Diseases & Practice
Open Access

Bacterial diseases; Natural catalytic antibodies; Bacterial toxins

Introduction

Bacterial diseases have been a significant health concern throughout human history, causing widespread morbidity and mortality. Traditional treatments like antibiotics have played a crucial role in combating bacterial infections, but the emergence of antibioticresistant strains poses a considerable challenge to modern medicine. As researchers search for alternative therapeutic approaches [1], recent advances in the field of immunology have revealed the potential of natural catalytic antibodies in the fight against bacterial diseases. These unique antibodies possess enzymatic properties, allowing them to neutralize bacterial toxins and enhance the immune response. This article explores the recent developments in natural catalytic antibodies research and their promising future directions as a novel therapeutic avenue for bacterial diseases.

Understanding natural catalytic antibodies

Antibodies are a vital part of the immune system, typically known for their role in recognizing and neutralizing foreign invaders such as bacteria, viruses, and other pathogens. Among these, natural catalytic antibodies stand out due to their additional enzymatic activity [2].

These antibodies, often referred to as abzymes, possess the ability to catalyze specific chemical reactions, contributing to the degradation of bacterial toxins and the promotion of immune responses.

Recent advances in natural catalytic antibodies research

Targeting bacterial toxins: One of the significant recent advancements in natural catalytic antibody research is their potential to target and neutralize bacterial toxins. For example, studies have shown that certain abzymes can efficiently degrade lipopolysaccharides (LPS), a component of the outer membrane of Gram-negative bacteria, which is known to trigger severe inflammatory responses in the host [3].

Enhancing antibacterial activity: Natural catalytic antibodies have been found to augment the immune system's ability to recognize and eliminate bacterial pathogens. By binding to specific bacterial surface antigens, abzymes can facilitate the opsonization process, leading to increased phagocytosis and clearance of bacteria by immune cells.

Antibody engineering: Researchers have made significant strides in the engineering of catalytic antibodies, improving their stability, specificity, and catalytic efficiency. These advances open up new possibilities for the development of targeted therapies against various bacterial diseases.

Combination therapies: Integrating natural catalytic antibodies with conventional antibiotic treatments has shown promise in combating antibiotic-resistant bacterial strains [4]. The synergistic effects of these combined therapies hold potential in overcoming bacterial resistance and reducing the dosage and side effects of antibiotics.

Future directions

The potential of natural catalytic antibodies in the management of bacterial diseases has sparked considerable interest among scientists and healthcare professionals. Several promising future directions are being explored:

Personalized antibody therapies: Advancements in biotechnology and antibody engineering techniques are paving the way for personalized antibody therapies [5]. Identifying and isolating abzymes from individual patients could lead to tailored treatments with enhanced efficacy and safety profiles.

Abzyme libraries and screening: The creation of vast abzyme libraries and high-throughput screening methods allows the rapid identification of novel catalytic antibodies with diverse specificities. This approach can expedite the discovery of new abzymes targeting different bacterial pathogens.

Application in biofilms: Bacterial biofilms are notoriously resistant to traditional antibiotic treatments. Harnessing the catalytic properties of antibodies to disrupt biofilms may offer a novel strategy to combat chronic bacterial infections [6].

Therapeutic applications in immunocompromised patients: Natural catalytic antibodies may hold particular promise for immunocompromised patients who are more susceptible to bacterial infections. Developing therapies that leverage the catalytic properties of antibodies could enhance the immune response in these vulnerable populations [7].

Much autoimmune pathology can be “activated” or “triggered” in clinically healthy women during pregnancy and soon after childbirth. Independent of the presence or absence of detectable autoimmune reactions in women during pregnancy, postnatal autoimmune pathologies, such as SLE, HT, phospholipids syndrome, polymyositis, autoimmune myocarditis, etc., may emerge. Autoimmunization of mothers during pregnancy similar to that occurring in autoimmune patients is very probable. The relative activities of Abzs from human milk can be significantly greater than those of Abzs with the same activities from autoimmune patients. Taking into account all these data, we believe that DNase and RNase pAbs of autoimmune patients and mother’s milk are “cocktails” of Abs against pure DNA and RNA and their complexes with various proteins, and antiidiotypic Abzs to active centers of different DNA-hydrolyzing enzymes including complexes of these enzymes with DNA and RNA. The central question is why autoimmunization of human mothers [8], autoimmune patients, and mice results in a dramatically higher incidence of catalytically inactive Abs and Abzs with enzyme properties as compared with healthy humans and animals.

Abs of healthy mammals possesses superoxide dismutase, H2O2- dependent peroxidase, and H2O2-dependent oxidoreductase activities. Therefore, it seems likely that some Abzs can reduce oxygen from O2 – to H2O2, while other Abzs neutralize the latter mutagen. We suggest that the specific repertoire of mammalian pAbs with these activities can serve as an additional natural system of detoxification of reactive oxygen species, and can destroy toxic, carcinogenic, and mutagenic compounds [9]. Specific stimulation of production of various Abzs by the mother’s immune system as a result of autoimmunization and infections may be a way of strengthening the protective function of breast milk Abs due to various Abz catalytic activities, and may play a very important role in the passive immunity of neonates and contribute to mucosal immunity by policing the function of some cells. Taken together, it is obvious that the biological roles of various Abzs may be very different. In the early stages of ADs, the repertoire of Abzs is usually relatively small, but it greatly increases with the progress of the disease, leading to the generation of catalytically diverse Abzs with different activities and functions. In this respect, it should be mentioned that even pools of Abzs from autoimmune patients contain different sets of Abzs, which may be toxic or nontoxic toward different cells; the number of toxic sets increased with development of deep pathology. It may be a consequence of an extreme diversity of the variable fragments and active centers of various Abzs [10].

Conclusion

Natural catalytic antibodies represent a fascinating area of research with immense potential in the fight against bacterial diseases. Recent advances have shed light on their ability to neutralize bacterial toxins, enhance the immune response, and combat antibiotic-resistant bacteria. As the field of immunology and biotechnology progresses, we can expect continued innovation in the development of personalized antibody therapies and novel strategies to target bacterial pathogens. The promise of natural catalytic antibodies offers hope for a future where bacterial diseases can be tackled more effectively, reducing the burden on healthcare systems and improving patient outcomes.

1. Smith MA, Seibel NL, Altekruse SF (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28: 2625–2634.

Indexed at, Google Scholar, Crossref

2. Soliman H, Agresta SV (2008) Current issues in adolescent and young adult cancer survivorship. Cancer Control 15: 55–62.

Indexed at, Google Scholar, Crossref

3. Meadows AT, Friedman DL, Neglia JP (2009) Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27: 2356–2362.

Indexed at, Google Scholar, Crossref

4. Schiffman JD, Geller JI, Mundt E (2013) Update on pediatric cancer predisposition syndromes. Pediatr Blood Cancer 60: 1247–1252.

Indexed at, Google Scholar, Crossref

5. Neale RE, Stiller CA, Bunch KJ (2013) Family aggregation of childhood and adult cancer in the Utah geneology. Int J Cancer 133: 2953–2960.

Indexed at, Google Scholar, Crossref

6. Magnusson S, Wiebe T, Kristoffersson U, Jernstrom H, Olsson H, et al. (2012) Increased incidence of childhood, prostate and breast cancers in relatives of childhood cancer patients. Familial Cancer 11: 145–155.

Indexed at, Google Scholar, Crossref

7. Friedman DL, Kadan-Lottick NS, Whitton J (2005) Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomark Prev 14: 1922–1927.

Indexed at, Google Scholar, Crossref

8. Mitchell ER, Scarcella DL, Rigutto GL (2004) Cancer in adolescents and young adults: treatment and outcome in Victoria. Med J Aust 180: 59– 62.

Indexed at, Google Scholar, Crossref

9. Trott PA (1977) International Classification of Diseases for Oncology. J Clin Pathol 30:782-783.

Google Scholar                   

10. Australian Institute of Health and Welfare (2013) Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol 23: 929–939.

 Indexed at, Google Scholar, Crossref